Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Novo Nordisk’s plummet is a warning for backers who’ve crowded into a relatively small group of very large stocks.

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in America. But just as these drugs are changing lives, a dangerous shadow ...

Plenty of folks have been using GLP-1s — generic knockoffs of popular weight loss drugs such as Ozempic and Zepbound — to jump-start their health journeys lately. But those folks could be in for bad ...

PG fell 0.3%, though it was hardly the worst-performing Dow Jones stock today. That honor went to UnitedHealth Group ( UNH ). The blue chip stock sank 7.5% after the country's largest health insurer ...

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...